Karykion, Inc was founded as a California corporation in 1971 with the objective to develop new antimicrobial antibiotic products.  The research resulted in the company's first patents for the preparation and water solubilization of amphotericinB and candicidin.  This started the first of many joint research efforts both commercially and academically.  The initial project included the participation of the University of California, Davis and E.R. Squibb & Sons.

The company was subsequently reincorporated in Delaware as a C corporation and then in 1997 in New Jersey as a S corporation.  Engaged in research and development activities including but not limited to the development of new polyene synthesis and new technologies and products for the treatment of fungal, viral and cholesterol related diseases.  The company is currently collaborating with the following organizations:

  • Boston Children's Hospital, Harvard University - Compositions of Ezetimibe and Methods for the treatment of Cholesterol-related Benign and Malignant Tumors.
  • Boston Children's Hospital, Harvard University -  Ezetimibe as an Inhibitor of Tumor Angiogenesis.
  • Boston Children's Hospital, Harvard University - The Role of Cholesterol in the Progression of Benign Prostatic Hypertrophy.
  • National Institutes of Health - National Cancer Institute - Frederick, Md.- Treatment of AIDS virus with Amphotericin Methyl Ester (AME).
  • Peter Gorer Department of Immunobiology - King's College London - Effects of AME on the function of Vpu in HIV replication.
  • Max Planck Institute for Cell Biology - Dresden, Germany - Virucidal activity of AME vs HIV.
  • Department of Neurotoxicology, School of Pharmacy - Rutgers University NJ - Studies of comparative neurotoxicology of amphotericinB and AME.
  • Walter Reed - Bethesda, Md. - Trials with AME for the treatment of Leishmaniasis.
  • US Army Research Center - Frederick Md.- Trials with AME for activity against Ebola Virus in Primates